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Introduction
A great variety of enteral formulae is available and it can become quite 
a challenge to decide on the most appropriate formula to prescribe 
for one’s patients at all times. Various classification systems can be 
used, but ultimately the following categories are primarily of the 
essence: polymeric, semi-elemental; disease-specific (which can 
be polymeric or semi-elemental) and modular1 (Figure 1). When 
deciding on the correct formula for a specific patient many factors 
need to be considered, and include both patient and formula related 
factors.1
Polymeric formulae
Polymeric formulae require normal digestion and absorption 
processes within the gastrointestinal tract (GIT) and macronutrients 
are used in intact form.2 These formulae are balanced (meeting 
100% RDA) for most micronutrients when between 1-1.5 litres of a 
given product is consumed daily.1-3 
Within the polymeric formula range there are wide variations with 
regard to energy and protein concentration, carbohydrate and fat 
content, as well as fibre content. The fluid content of a specific 
formula is affected by the concentration of macronutrients (Table 1). 
The availability of various enteral formulae on the market assists in the individualized management of patients. It provides variety in terms 
of macronutrient content, fluid options and the addition or omission of certain components, e.g. fibre, electrolytes and immunonutrients. 
It is imperative that health care practitioners should be familiar with all products locally available and should have the ability to select the 
most appropriate products to meet the patient’s needs. We provide a brief summary of all enteral formulae in terms of unique features and 
recommendations for use. Practical application is discussed by means of two case studies.
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Case Study:  
Enteral formula: Selecting the 
right formula for your patient
Figure 1. Enteral formula classification
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Semi-elemental formulae
To assist with the digestion and absorption of nutrients, semi-
elemental formulae contain macronutrients that are hydrolyzed 
(partially or fully).1,3,4,5 These products will typically be used for 
patients with an impaired GIT (surgery or disease affecting the total 
available surface length, or exocrine pancreatic insufficiency).3,4 
Although these products are not intended for routine use,1,2,3,4,6,7 
patients with severe malnutrition and hypoalbuminemia where GIT 
oedema and resultant malabsorption is expected, as well as patients 
with GIT impairment and patients who did not tolerate (failed 
management) a polymeric formula will likely benefit from semi-
elemental enteral products1,4 (Table 1).
Disease-specific formulae 
Specialized enteral formulae comprise of a wide range of formulae 
tailored for a variety of clinical scenarios. The aim is to improve 
patient outcome. However, this might not always be supported by 
scientific evidence.1 It should be noted that a wider range of disease 
specific enteral formulae exists in the international market than what 
is available in the South African context. For the purpose of this case 
study we will only refer to products available for use in South Africa 
(Table 1).
Diabetes Mellitus (DM)
Enteral formulae can be used to assist in glucose control of patients. 
This can be achieved through the addition of fibre to a polymeric 
formula, or through strict calculation of the macronutrient composition 
of the desired product. Products specifically marketed for glucose 
control are based on a more or less equal carbohydrate to fat ratio 
or a lower carbohydrate, higher fat content.1,3,8,9 Emphasis is also 
placed on the type of fat (mono-unsaturated fatty acids), the addition 
of fibre (usually a blend of different fibres) and the addition of selected 
micronutrients (chromium, antioxidants).1,3,4,8,9 The rationale is that 
the addition of the fibre and fat will assist in glucose management 
by controlling gastric emptying, as well as the rate of absorption of 
glucose throughout the GIT.3 This approach might be desired in a 
patient with normal GIT function, but could worsen symptoms of poor 
enteral feed tolerance in a patient with gastroparesis.3,4,5 The practice 
recommendations for macronutrient distribution in the management 
of DM have changed in recent years with an emphasis on total energy 
Table 1: Summary of characteristics of enteral formulae and recommendations for use1,2,3,4,6
Category Characteristics Recommended usage
Polymeric • Mimics macronutrients as found in whole food
• Available with different energy densities  
(1–2 kCal/ml)
• Available with different protein contents (40– 100 g/
litre)
• Available with or without fibre
• Meets RDA for micronutrients in  
1–1.5 litres/day
• Isotonic, polymeric formulae is regarded as a safe option when 
initiating enteral feeding 
• For use in patient populations without malabsorptive disorders
• High energy and protein formulae for use in patients with enhanced 
requirements
• High energy and protein formulae for use in fluid restricted patients
• Fibre could decrease the incidence of diarrhoea and improve gut 
microbiota
• Fibre could play a beneficial role in blood glucose control
• Fibre-containing products are recommended for patients receiving 
long-term enteral formula to prevent and treat constipation
Elemental or 
semi-elemental
• Macronutrients are hydrolysed to aid in absorption 
• Available in different energy and protein densities
• Patients with impaired GIT functioning/malabsorption
• Patients post GIT surgery with reduced absorptive area and/or 
prolonged bowel rest 
• Patients with a chyle leak 
• Patients with pancreatic dysfunction 
• Patients with severe malnutrition and hypoalbuminemia, with 
resultant gut oedema and malabsorption
Diabetes • Modified macronutrient composition to promote 
glycaemic control
• Higher fat content and fibre to slow gastric 
emptying and prevent hyperglycaemic episodes
• Could be used for patients with Diabetes Mellitus, if adequate blood 
glucose control cannot be achieved through standard polymeric 
formulae
• Be cautious of the high fibre and fat content of the products in 
patients with gastroparesis
Low sodium • Polymeric formulae with reduced sodium content • For use in patients with persistent hypernatremia
Renal • Higher energy and protein content to limit excessive 
fluid administration
• Contain lower amounts of electrolytes, specifically 
potassium and phosphorus
• Available in different protein contents
• Most patients with renal impairment can be managed by standard 
polymeric products with additional protein content
• Persistent electrolyte abnormalities that cannot be managed by 
standard enteral formulae require specialized renal formulae
Respiratory • Modified macronutrient content to reduce carbon 
dioxide production.
• Contains omega-3 fatty acids for their  
anti-inflammatory properties.
• Should be used with caution in critically ill, septic patients, due to the 
immunonutritional components added
• Can be used for patients where efforts to manage respiratory quotient 
(excess carbon dioxide production) have been unsuccessful 
• Care should be taken not to overfeed patients 
Oncology / immune 
modulating
• Contains pharmacologically active substances 
aimed at modulating the immune response and 
improving outcome
• Potential benefit in patients undergoing elective surgery, however 
cannot be recommended for routine use among critically ill patients
RDA = Recommended daily allowance; GIT = Gastro-intestinal tract
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control and less focus on the specific macronutrient composition.10 
The composition of the enteral formulae available is thus not in line 
with current recommendations.1,3 This will however not cause harm 
as long as the patient is not overfed and is adequately monitored. 
The use of specialized diabetes enteral formulae is recommended 
by some9; others, however, advocate standard polymeric formulae, 
preferably with fibre as suitable for use as enteral formula in patients 
with DM.1,8 It remains of paramount importance though, in clinical 
practice, to carry out daily monitoring and adjustment of the formula 
until adequate blood glucose control is achieved. 
Renal
Many factors affect the medical and nutritional management 
of a patient with renal impairment. Protein, sodium, potassium, 
phosphorus and fluid restriction need to be considered. Enteral 
formulae marketed specifically for patients with renal impairment 
address these aspects by either decreasing or increasing the 
respective nutrients within a given volume.1,3,4,5 It remains the 
responsibility of the health practitioner to select the most suited 
product considering all relevant aspects. In the majority of cases, 
standard polymeric formulae could be used as the first line of 
management. However, persistence of a specific electrolyte 
abnormality necessitates the use of a relevant renal formula until the 
abnormality resolves.1,3  
Pulmonary
The basis of nutrient manipulations in pulmonary formulae are 
centred around lessening the amount of carbon dioxide production in 
an effort to reduce the respiratory quotient (RQ).1 Since carbohydrates 
contribute the most to RQ, these products decrease the carbohydrate 
contribution (± 30%) and increase the amount of fat (± 50%), with 
relatively similar protein contents.3,4 Another specific component of 
pulmonary products is the fatty acid composition used. The addition 
of omega-3 fatty acids, as well as gamma-linolenic acid (GLA) 
reflect an attempt to enhance the anti-inflammatory properties of 
products for use in patients with acute lung injury (ALI) and acute 
respiratory distress syndrome (ARDS).3,4 Conflicting data exist on the 
clinical benefit of these formulae.1,6,7 The practice of manipulating 
the macronutrient contribution in assisting with weaning patients 
from a ventilator is, however, no longer regarded as the best manner 
to achieve these outcomes. Prevention of overfeeding by decreasing 
the total energy prescribed has been shown to achieve similar 
results.1,3,4,6 Therefore, a standard polymeric formula, with possibly 
less volume, is regarded as the recommended approach.1 
Immunonutrition
Immune modulating formulae, or immunonutrition, refers to products 
that contain pharmacologically active substances such as glutamine, 
arginine, omega-3 fatty acids and antioxidants, amongst others. In 
this case the goal of enteral nutrition is not only to provide sufficient 
macro- and micronutrients, but also to modulate the immune system 
to improve outcome. These products are mainly recommended for use 
in elective surgery patients. The data is not sufficient to recommend 
routine use among critically ill patients.1,3 Recommendations on 
the use of these products differ between patient populations, the 
specific pharmaco-nutrient(s) added and different guidelines by 
various Societies. Discussion of these different guidelines is beyond 
the scope of the objectives of this clinical practice presentation. 
Modular formulae
Single-nutrient products (protein, carbohydrate and fat modules) are 
available. These are mainly used to enrich existing formula,1 (e.g. 
adding additional protein to an existing product), but can also be 
used to create a tube feed from individual modular components, with 
the addition of required micronutrients. It is important to ensure that 
good hygiene principles are employed when modular components 
are added to existing formula or used to make up a tube feed. 
Introduction to cases
Two different case studies will be used as examples. The various 
categories of products (as available in South Africa) illustrate the 
thought process underlying the enteral feed selection. Although 
these guidelines can be used as default recommendations, 
ultimately disease-specific recommendations must be employed 
where applicable.
Case 1:
Mr K is a 62-year-old male transferred to the intensive care unit (ICU) 
from a peripheral hospital with respiratory failure and prolonged 
ventilation. He underwent a laparotomy 17 days prior to transfer 
due to colonic obstruction. At laparotomy he was found to have a 
gangrenous caecum and a right hemi-colectomy was performed, 
with an end-ileostomy and mucus fistula. On presentation in ICU he 
was found to have skin dehiscence of the laparotomy wound, but the 
sheath was intact.
Anthropometry on admission was based on height derived from 
ulnar length and an estimated body mass index (BMI) and weight. 
Height: 1.72 m Weight: 80 kg BMI: 27 kg/m2. Ideal body weight was 
calculated as 74 kg at a BMI of 25 kg/m2. 
Relevant biochemistry is presented in Table 2. The patient 
presented with acute kidney injury but was not yet referred for renal 
replacement therapy (RRT).
On clinical examination the patient was intubated and ventilated 
and required inotropic support. He had oedematous extremities and 
pulmonary oedema. Abdominal examination revealed a dehisced 
skin incision with a vacuum dressing and minimal output. The 
stoma in the left lower quadrant had no output since admission. The 
nasogastric tube had minimal drainage of 10 ml. 
The patient’s recent dietary history was unclear from the referring 
hospital. There was concern regarding enteral tolerance and it was 
decided to start parenteral nutrition (PN) due to the fact that he 
already had a prolonged ICU stay. Enteral nutrition (EN) was also 
initiated at a low rate.  
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Requirements were calculated using the European Society for 
Clinical Nutrition and Metabolism (ESPEN) ICU guidelines7 of 
25–30 kCal/kg total energy (TE), while protein requirements were 
calculated at 1.2–1.5  g/kg. Ideal body weight was used in the 
calculations. This amounted to 1850–2220 kCal TE and 89–111 g 
protein.
The patient’s immediate ICU course was complicated by poor EN 
tolerance but on day three post admission he was weaned off PN 
onto a concentrated semi-elemental enteral formula providing 
1.3 kCal/ml and 67 g protein/L @ 63 ml/hr (1500 ml per day). This 
provided 1950  kCal TE and 100  g protein. The choice of semi-
elemental formula was made on the basis of severe fluid overload 
with clinical oedema on the background of hypoalbuminemia and a 
prolonged period of little to no enteral stimulation. The assumption 
was made that the patient might have gut oedema and poor 
tolerance of polymeric enteral formula. Due to the renal failure and 
low urine output the patient was fluid restricted which necessitated 
the use of a concentrated enteral formula in order to meet calculated 
requirements.  
On day three post admission the patient’s renal function deteriorated 
further and RRT was started in the form of intermittent haemodialysis 
(IDH). Protein requirements were recalculated using the American 
Society for Parenteral and Enteral Nutrition (ASPEN) guideline6 taking 
into consideration RRT at 1.5–2.5 g/kg depending on the mode of 
dialysis. Protein goal was set at 111–185  g protein per day. The 
patient was however fluid restricted to 1500 ml of enteral formula 
and was already receiving the most concentrated, highest protein 
containing semi-elemental formula available in the institution. 
Protein requirement could therefore not be met. Feed was continued 
at 63  ml/hr as described above. The patient required one day of 
dialysis only. 
Daily review of the biochemical parameters revealed a steady 
increase in the patient’s serum sodium level reaching 152 mmol/L 
by day 9. The patient was started on additional water at 21 ml/hr 
via the nasogastric tube while EN continued at 63 ml/hr. This was 
initiated on the assumption that the patient could be dehydrated 
due to conservative fluid management. Serum sodium however 
remained on an increasing trend. The stoma output was well 
controlled and remained well below 1000 ml per day. In the light of 
the electrolyte abnormality and the clinical picture, the decision was 
made to challenge the patient with a low sodium content polymeric 
formula. The EN prescription was changed to 500 ml of a polymeric 
enteral product providing 1.5 kCal/ml, 100 g protein/L, and 21 mmol 
sodium/L with an additional 1500 ml of a polymeric enteral product 
providing 1  kCal/ml, 40  g protein/L, and 11  mmol sodium/L. The 
total prescription provided 2000  ml, 2250  kCal TE, 110  g protein 
and 27 mmol sodium. He remained on this prescription for 19 days 
before his sodium normalised. Patients with renal dysfunction should 
not be managed on low electrolyte formula routinely. However, 
should a specific electrolyte abnormality occur, like in this case, an 
appropriate formula should be considered to correct it. 
Case 2:
Mr X is a 20-year-old male admitted to ICU post sternotomy for a 
single stab to the chest. He required intubation and ventilation 
for airway protection due to facial swelling secondary to venous 
occlusion. Oesophageal injury was excluded. He had no previous 
medical history of note and was a healthy, fit individual according to 
information obtained from his family. 
Anthropometry on admission was an estimated weight of 
63 kg, height (derived from ulnar length) of 1.65 m and a BMI of 
23  kg/m2. Biochemistry was essentially normal. On clinical 
examination the patient was intubated and ventilated, but awake 
and able to respond. He was kept intubated due to severe facial 
swelling. His abdomen was soft and unremarkable. 
From a dietary point of few he was started on naso-gastric feeds and 
increased to 84 ml/h of a polymeric feed over the first 48 hours of ICU 
admission providing 1 kCal/ml and 38 g protein/L. This provided a 
total of 2000 kCal and 76 g protein. It is recommended that standard 
polymeric formula be used when initiating enteral feeding in most 
patients.1,6,7 The nutritional requirements were calculated using 
the ASPEN guidelines6 for ICU of 25–30 kCal/kg TE and 1.2–2 g/kg 
protein. Actual body weight was used in the calculations and came 
to 1575 – 1890  kCal TE and 76–126  g protein. Due to the facial 
swelling a decision was made to reduce his total fluid volume and 
his feed volume was restricted to 1500 ml per day. 
In order to meet his calculated requirements in the reduced volume, 
his enteral feed prescription was changed on day 3 post admission. 
The script included 500 ml of a polymeric enteral feed formula that 
provides 1.5 kCal/ml and 100 g protein/L combined with 1000 ml 
of a polymeric enteral feed formula that provided 1  kCal/ml and 
38  g protein/L. The combination of formula provided 1750  kCal 
TE and 88  g protein in the allowed 1500  ml, meeting calculated 
requirements. Adding additional protein to standard polymeric feeds 
Table 2:Case 1 Biochemical results
Unit Normal Admission Day 1 Day 3 Day 9 Day 10 Day 11 Day 22 Day 28
Sodium mmol/l 136 – 145 139 139 139 152 156 160 148 144
Potassium mmol/l 3.5 – 5.1 3.2 3.7 4.1 3.7 3.6 3.4 3.5 4.2
Urea mmol/l 2.1 – 7.1 21.2 24 28.7 13.6 13.6 9.8 8.4 10.7
Creatinine umol/l 64 – 104 360 318 364 127 127 107 65 64
Magnesium mmol/l 0.6 – 1.05 0.76 0.88 0.98 - - - - 0.8
Phosphate mmol/l 0.78 – 1.42 1.71 1.28 1.57 - - - - 1.23
Albumin g/l 35 - 55 17
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has the advantage of meeting patients’ nutritional requirements, 
without having to increase the total amount of feed delivered. 
When prescribing high protein formulae it is important to monitor 
renal function and hydration status. A high protein load could result 
in an increased free water excretion, hypertonic dehydration and 
hypernatremia. The advantages of higher concentration feeds are that 
less volume is required to meet individual patient needs. Therefore, 
patients with high nutritional requirements, in combination with fluid 
restriction, as well as patients receiving enteral feeds over less than 
24 hours, can benefit from using concentrated feeds.1,3 A potential 
side-effect of a concentrated feed is a tendency to draw water into 
the GIT due to the osmotic effect of a high concentration solution. 
This can result in osmotic diarrhoea.2 
On day 4 post admission there was a slight improvement in his facial 
swelling. Examination of his upper airway under sedation however 
revealed on-going swelling and inability to safely extubate. He was 
considered for a percutaneous tracheostomy for prolonged ventilation 
and his feed was discontinued the next morning for the procedure. 
He developed a temperature of 38oC possibly secondary to ventilator 
associated pneumonia. His enteral feed was recommenced after 
placement of the tracheostomy and was restarted at an increased 
rate of 84 ml/hr to compensate for the time that he was kept nil 
per os (NPO). Follow-up on day five post admission revealed that 
he received 1350 ml of his prescribed 1500 ml of enteral formula in 
previous 24 hours. It was noted that the patient had not passed any 
stools since admission to ICU. His abdomen was slightly distended 
but soft and not tender. A decision was made to increase the fibre 
content of his enteral formula due to the fact that he was expected 
to be a long term enterally fed patient. He was kept on the 500 ml 
of enteral formula providing 1.5 kCal/ml and 100 g protein/L since 
it also included 12 g of 100% soluble fibre per litre. The 1000 ml 
of standard polymeric formulae was changed to a fibre containing 
formula, which provided 1 kCal/ml, 38 g protein/L and 15 g fibre/L 
(Soluble:Insoluble 61:39). This provided a total amount of 21  g of 
fibre. On day 7 post admission the patient had passed two soft stools 
and his abdominal distention resolved. He was continued on this 
prescription for another three days before he was safely extubated 
and transitioned to oral nutrition. 
The fibre content of the various products ranges from none to 20 g/L. 
Usually a blend of different fibres (soluble, insoluble and prebiotics) 
is used to ensure best results.2 The type and amount of fibre should 
be selected based on the individual patient’s needs. Soluble fibre is 
best prescribed for patients suffering from osmotic diarrhoea, since 
soluble fibre has the ability to absorb water and form the stool bulk.2 
On the other hand, insoluble fibre is not digested and increases faecal 
weight,1,2 which is important for the management of constipation. 
Fermentation also results in the formation of short-chain fatty acids 
(SCFA), which provides the main energy source for the colonocytes, 
and thus aid in the establishment of a healthy microbiome 
environment.1,2,4 The fermentation process can aid in gas production, 
which can cause abdominal distension and discomfort.1 It should be 
ensured that the fibre content of feeds is increased gradually, and 
that sufficient fluid is consumed with a fibre-containing formula.4 
Fibre can also assist in maintaining of blood glucose levels.4 By 
combining different fibre types, the enteral formula has the ability to 
perform various positive effects simultaneously. It is also important 
to remember that the digestion of fibre is a metabolic process that 
requires adequate blood supply and a healthy gut. In patients with 
haemodynamic instability and in the presence of hypotension, it 
is not advisable to prescribe fibre due to the danger of ischaemic 
damage to the small bowel.2-4,6 For this reason, many patients in ICU, 
especially during the first few days of treatment, should not receive 
a fibre-containing formula.6
Conclusion
There are various factors to consider when selecting an appropriate 
enteral formula. It is important to evaluate each patient individually 
and to make evidence-based decisions. Patient-specific nutritional 
and medical requirements are of the utmost importance. However, 
Table 3. Factors to consider when selecting the most appropriate enteral formula
Category Sub-category Specific component
Patient related Medical situation • Medical history and management
• Surgery, especially related to GIT
Nutrition status assessment • Presence of malnutrition
• Food allergies
• Period of nil per mouth
Management of complications • Disease-specific requirements
• Biochemical abnormalities
• GIT malabsorption / diarrhoea / constipation
Nutritional prescription Access routes • Naso/oro gastric versus small bowel access
Nutritional requirements • Total energy and macronutrient distribution
• Fibre needs
• Micronutrient needs
• Total fluid requirements
Implementation of feed Administration method • Continuous over 24 hours versus cyclic over 18 hours versus bolus feeds
• Availability of feeding pumps
Logistical matters Available resources • Budget
• Tender specifications / restrictions
• Available staff
• Mixing facilities
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logistical aspects including cost, availability of resources and tender 
specifications cannot be ignored (Table 3). It should also be kept in 
mind that it can become quite a challenge to select the best product 
in the correct amount(s), meeting nutritional requirements at all 
times. 
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